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Objectives: 4220 new cases of tuberculosis (TB) were reported in Germany in 2012; of those,
65 cases were multidrug-resistant TB (MDR-TB) or extensively multidrug-resistant TB (XDR-TB)
cases. However, there is only limited information on the economic consequences of drug resis-
tance patterns on the treatment costs of MDR-and XDR-TB patients.
Methods: On the basis of drug susceptibility of the single MDR-TB/XDR-TB strains the direct
medical costs of suitable therapies were calculated according to the current guidelines of
the World Health Organization (WHO) and those of the German Central Committee against
Tuberculosis. These costs were combined with hospital and outpatients monitoring costs and
followed the most recent German invoicing system and health statistics. Total drug and moni-
toring costs and were determined by Monte-Carlo simulation comprising all different options.
Results: According to this, the mean drug costs were V51,113.22 (range V19,586.14 to
V94,767.90). The weighted costs for hospitalization were V26,000.76 per patient compared
to only V2,192.13 for primary outpatients; the total treatment costs of MDR-TB amounted
to V64,429.23.
These are joined by the costs due to loss of productivity, varying between V17,721.60 and
V44,304. From a societal perspective, the total cost per MDR-TB/XDR-TB case reach an amount
between V82,150 and V108,733 per case, respectively.
Conclusion: Cost analyses based on strain resistance patterns allow more reliable estimates of
the real costs of treating MDR-TB/XDR-TB than do methods that ignore this factor.r Epidemiology, University Medical Hospital Schleswig-Holstein, Niemannsweg 11, 24105 Kiel, Ger-
þ49 (0) 4315973730.
i-kiel.de (R. Diel).
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1678 R. Diel et al.Advantageously, they demonstrate the economic impact of drug-resistant TB in low-incidence
countries. Costs of productivity loss is of new importance because of the length of MDR-XDR
therapy, but its true share of total costs has still to be determined.
ª 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Table 1 Age, Gender and hospitalization of the 65 MDR-
TB patients reported to the RKI in 2012.
Patients not hospitalized (or without hospitalization
information*)
Age Gender
17 Female (*information on hospitalization
not available)
18 Female
24 Male
25 Female
25 Female
30 Female
36 Male
37 Male (*information on hospitalization
not available)
52 Male
Patients hospitalized
Age Gender Age Gender Age Gender Age GenderIntroduction
Despite globally declining tuberculosis (TB) incidence rates,
multidrug-resistant TB (MDR-TB), defined as simultaneous
resistance to at least the most powerful anti-TB drugs,
isoniazid (H) and rifampicin (R), remains a major public
health challenge in Europe. In 2012, 15 of the 22 countries
considered “MDR-TB high burden” belong to WHO European
region [1,2] in which the prevalence of MDR-TB among
90,127 new TB cases tested for first-line drug susceptibility
was 15% [3]. 978 MDR-TB were reported accounting for 4.6%
(range 0e25.5%) of all new and retreatment TB cases [3]. Of
all MDR-TB cases tested for second line drugs 127 (or 14.9%)
were determined to be extensively-drug-resistant. (XDR-
TB), characterized by an additional resistance to a fluo-
roquinolone and to one or more of the injectable drugs [3].
Compared to drug-susceptible TB, treatment of MDR-TB
and XDR-TB consumes significantly higher resources due to
its longer duration with a number of more costly drugs.
Furthermore, therapy may be more complex than the
general definitions for MDR-TB and XDR-TB indicate; it be-
comes highly individual as concomitant resistance patterns
of the respective strains against further anti-TB drugs exist.
More accurate cost figures per case and in total are
necessary for the rational resource planning required of
health care providers in Germany. This is all the more
important as numbers of MTB-TB are expected to increase,
due predominantly to continued immigration from high-TB
prevalence states of the former Soviet Union (NIS) [4].
To date, however, in Germany as well as throughout
Europe, data about the cost of treating MDR-TB that takes
into consideration the various resistance characteristics of
MDR-TB/XDR-TB are completely lacking. To close this gap,
we have addressed that topic in our new cost analysis based
on the susceptibility differences observed between MDR-TB
strains on a national level in 2012.17 Female 28 Female 38 Male 48 Male
18 Male 29 Male 39 Male 49 Male
19 Female 29 Male 39 Female 50 Male
19 Female 31 Male 39 Male 52 Male
21 Male 32 Female 40 Male 53 Male
22 Male 32 Male 40 Male 55 Male
22 Female 33 Male 40 Female 57 Female
22 Female 35 Female 40 Male 60 Male
23 Male 35 Female 40 Male 68 Female
25 Female 35 Female 42 Male 71 Male
26 Male 35 Male 45 Male 73 Male
27 Male 37 Male 46 Female 74 Female
27 Male 37 Male 47 Male 80 Female
27 Female 38 Male 48 Male 87 Male
MDR-TB Z Multidrug Resistant Tuberculosis.Epidemiological data for MDR TB/XDR-TB in
Germany
The Robert Koch Institute (RKI) in Berlin received notifica-
tion of a total of 4220 TB cases from Germany for 2012,
which calculates to a TB incidence rate of 5.2 cases per
100,000 population [4]. The proportion of throughout pul-
monary MDR-TB increased from 1.8% (54 cases) in 2011 to
2.3% (65 cases) in 2012, of the 2989 cases for whom infor-
mation on strain resistance against H and R was reported,
or 1.54% of all 4220 reported TB cases. Of the 65 MDR-TB
patients, 57 were treated in hospital (87.69%) for a mean
duration of 89.06 days [5]; of these all but 2 (with 3 and 8days hospital treatment, respectively) were hospitalized
longer than 14 days.
There were 41 male MDR-TB patients (63.1%) and 24
female (36.9%). The mean age of these patients was 38.5
years (SD  16.06); the median was 37 (range 17e87 years).
The full list of the 65 MDR-TB patients showing age and sex
is provided in Table 1.
Calculation methods
This analysis considers only the charging of costs which are
legally mandated or that are due to procedures repre-
senting “state of the art” of therapy of active disease. From
the societal point of view, the following cost categories are
Cost of multidrug resistance tuberculosis in Germanydefined and calculated, if possible, based on the most
recent available data in each case:
1.) Direct costs for diagnosis and therapy of tuberculosis
bourn by the GKV comprising the weighted averages
of the following items:
a) Hospitalization costs
b) Outpatient costs, stratified into primary outpa-
tient costs (no hospitalization during treatment)
and secondary outpatient costs (following initial
hospitalization)
c) Drug acquisition costs (weighted average of
treatment included)
d) Treatment monitoring costs (weighted average of
treatments included)2.) Indirect costs dues to loss of productivity on the part
of the general economy.
Our calculations of the direct costs are based on the
rates established by the Statutory Health Insurance Scheme
(Einheitlicher Bewertungsmabstab, EBM) [6] for ambulatory
services and on data provided by the InEK (Institute for the
Hospital Remuneration System) data for the German
Diagnosis-Related-Groups (DRG) system [7]. They are
explained in detail in the section of “Supplementary
Material“. The loss of productivity from the point of view
of the general economy is then calculated on the basis of
the gainfully employed rate (share of the 15e65 year olds in
the country’s population that are gainfully employed).
The catalogue of diagnostic and monitoring procedures
for MDR-TB TB is strictly defined by current joint guidelines
of the German Central Committee against tuberculosis
(DZK) and the German Respiratory Society for TB therapy
[8], which adopted the new WHO guidelines on therapy for
MDR-TB [9] and by the Partners in Health (PIH) guide [10].
However, its economic translation in terms of for which the
GKV will pay had to be revised as a new EBM came into
effect on 01 April 2014 completely adjusting the compen-
sation for physician services. Confidence intervals for
monitoring costs are not provided, as their application to
this non-probabilistic billing system would have been
inappropriate.
Basic presumptions of cost calculations of
outpatient treatment
To avoid overestimation of the actually costs incurred, we
assumed that the responsibility for management of diag-
nosis and therapy for primary outpatient treatment or
secondary outpatient treatment following initial hospitali-
zation lies with the general practitioner throughout the
disease. For purpose of simplification, the general practi-
tioner who will either refer the patient directly to the
hospital where the patient will start the diagnostic pro-
cedures and therapy as primary inpatient or, alternatively,
to the private lung specialist who will care for the patient
as primary outpatient.
If there were fee schedule positions in the EBM for
different age groups, we used the respective most probable
position (younger adults) where MDR-TB disease in Germany
is most prevalent.Although numerous side effects can occur throughout
therapy, costs for adjuvant medication do not apply, as no
routine data on actual frequency and severity with respect
to interruption or prolongation of MDR-TB treatment have
so far been collected. However, in derogation from previ-
ous cost calculation of monitoring during therapy [11], we
also included monitoring with respect to eventually severe
side effects of group 5 drugs (e.g. Linezolid [LIZ]).
Thus, monitoring of the following laboratory parameters
has been considered:
1. Serum electrolytes including magnesium and potassium,
liver function and renal function values are checked
monthly in all patientswhile receiving the injectabledrugs.
2. Hypothyroidism, a possible side effect of prothionamide
or PAS is diagnosed by checking the serum level of TSH at
least every 6 months.
3. Ophthalmic examination is performed, linezolid treat-
ment before therapy starts and usually every 4 weeks.
4. Audiometry in the initial phase and then every 4 weeks
during therapy with injectable drugs (e.g., amikacin) in
MDR patients, 10 times in total.
5. X-rays (given pulmonary TB): in the initial phase, after 4
weeks (to control if the TB is reacting to the therapy), and
after 8 weeks (end of the initial therapy: success assess-
ment). After 8 weeks, x-ray check-ups in the 4th and 6th
monthare sufficient, followedbycheck-upsevery3months
and 3, 6, 12, and 24 months after the end of treatment.
6. ECG monitoring when using drugs may prolong QTc
(levofloxacin, moxifloxacin, clarithromycin, clofazi-
mine). ECGs at 0, 2, 12, and 24 weeks is recommended.
7. Estimates of the frequency with which computer tomog-
raphy is used as a diagnostic supplement in unclear radio-
logic casesorobserving the remissionof tuberculous lesions
were not available and thus cost data were not included.
The most recent WHO guidelines propose a fixed regimen
schedule combination that should include at least pyr-
azinamide added to a minimum of 4 second-line anti-TB drugs
that are likely to be effective: a fluoroquinolone, a parenteral
agent (kanamycin, amikacinor capreomycin),ethionamide (or
prothionamide), and either cycloserine or PAS [9]. In addition,
in the current version, a prolonged intensive phase of 8
months’ duration (including the parenteral agent) is consid-
ered necessary instead of the previous minimum of 6 months
and a total duration of treatment of at least 20 months.
In Germany, however, drug susceptibility testing (DST) is
well established allowing modifications to the WHO “stan-
dard” regimen if further information on eventual resistance
is provided. According to the remaining in vitro-suscepti-
bility of the respective MDR-TB strain a regimen of at least
5 drugs considered effective in vitro is recommended and a
reduction of the number of prescribed drugs is discouraged
for fear of eventual treatment failure.
As group 1 (first-line) drugs are the most potent and best
tolerated, as many drugs as possible should be incorporated
into the therapeutic regimen (if good laboratory evidence
suggests that a drug from this group is effective) [12] and
linezolide (LIZ) if there is resistance against quinolones to
increase the chances for a favorable outcome [13,14].
Resistance patterns of MDR-TB and XDR-TB, as far as DST
was performed in Germany, are collected in the National
1680 R. Diel et al.Reference Center (NRZ, Nationales Referenzzentrum) for
Myobacteria in Borstel, Germany. As the actual composition
of drug alternatives administered to MDR-TB patients in
Germany is not known, an appropriate therapy schedule for
each investigated strain had to be assessed individually and
its cost calculated. From the perspective of incurring costs,
the least expensive regimen has to be chosen. Drug costs
were determined by selecting the least expensive manu-
facturers from the pharmacy retail prices (Apoth-
ekenverkaufspreis, AVP) as shown in the ROTE LISTE, the
register for pharmaceutical drugs in Germany“ 2014 [15].
The drugs with their abbreviations used in the model are
listed in Table 2 in alphabetic order.Drug costs for treatment regimen of MDR/XDR-
TB in Germany
In 2012, from the total of 65 cases of MDR-TB/XDR-TB re-
ported to the RKI, the resistance patterns for new 55 cases
could be provided by the NRZ as follows:
39 MDR-TB strains without “second line”-drug resistance
with resistance.
a) 19 strains to H plus R and 1 strain to H plus R plus E (in
these 20 cases WHO standard regime could be used
which basically included Z),
b) 4 strains to H plus R plus Z (here Z could be replaced by
E),
c) 15 strains to H plus R plus E plus Z (here LFX and LIZ
replaced E and Z).
The remaining strains had “second line”- drug resistance:
d) 4 strains to H plus R plus all FQ (here E was used instead
of the FQ) and one strain susceptible only to MOX (here
the WHO standard regime could be used),
e) 7 strains to H plus R plus injectable drugs of which 3
were resistant to AMK and CM (but susceptible to E) and
4 were resistant to AMK solely (replaced by CM).Table 2 List of medical drugs for TB treatment available in Ge
Name Abbreviat
Amikacin FRESENIUS AMK
Amoxicillin/Clavulansa¨ure Amoxi-saar plus 875/125 AMX
Capreomycin CAPASTAT King Pharmaceuticals CM
Clarithromycin-ratiopharm 500 mg CLAM
Clofazimin (LAMPREN) 100 mg CLO
Ethambutol (EMB-Fatol) 400 mg E
Isoniazid 300 mg ISOZID Comp H
Levofloxacin AL 500 mg LFX
Linezolid ZYVOXID 600 mg LIZ
Moxifloxacin AVALOX 400 mg MOX
PAS-FATOL 13.5 g PAS
Protionamid PETEHA Riemser 250 mg PTH
Pyrazinamid JENAPHARM 500 mg Z
Rifabutin MYCOBUTIN PFIZER 150 mg RBT
Terizidon 250 mg TZAnd 4 strains were XDR-strains with the following
resistance:
f) 2 strains to H, R, E, Z, SM, RBT, PTH, AMK, CM, Ofl, LFX,
MOX (2 different combinations were used including LIZ,
PAS, TZ),
g) 1 strain to H, R, E, Z, SM, PTH, AMK, CM, Ofl, LFX, MOX,
but susceptible to RBT (LIZ, PAS and TZ plus RBT and
CLO),
h) 1 strain to H, R, E, Z, SM, RBT, PTH, AMK, CM, Ofl, LFX,
MOX, PAS (LIZ and TZ plus AMX, CLAM and CLO).For all treatment options it was assumed that the
intensive phase would be fulfilled as requested by the
guidelines (240 days) with a total duration time of 20
months (600 days). For that purpose, the daily dose of LIZ
was reduced to 300 mg that has been shown to drastically
decrease adverse side effects but with comparable efficacy
as a 600 mg dose [16]. For the application of injectable
drugs, access via a venous port was presupposed. The daily
therapy costs were calculated from the quotient between
the intake quantity stated in the dosing instructions and the
pack quantity.
The costs of the regimes under consideration, separated
by outpatient costs and costs following primary hospitali-
zation are depicted in detail in the Table 3 (Tables
3.1e3.10). Of note, according to the current contract of
nursing services with the AOK [17], intravenous adminis-
tration of injectable drugs will be paid with V18.30 for 1
tour per day and V32.95 for 2 tours per day in Germany.
Finally, a Monte Carlo simulation was performed under
the assumption that 1000 MDR-TB patients would undergo
therapy in the future. To reflect the actual strain resistance
patterns costs for medication of different therapy options
were weighted according to the distribution of regimens
listed above (see Fig. 1 for primary outpatients).
Accordingly, the mean costs for medication for primary
outpatients are V 51,113.22 (95% CI V50,172.53 to
V52,053.90, see Table 4) with a range of V19,586.14 to
V94,767.90. After initial hospitalization (subtracting 89rmany.
ion Form/price Daily dose
10 Infusion bottles -Fl.
500 mg/100 mL: V350.88
2  1:V70.17
24 film-coated tablets: V66.13 2  1: V5.51
1 vial 1000 mg: V149.35 1 vial: V149.35
20 film-coated tablet: V19.33 2  1: V1.93
100 tablets: V183.35 1  1: V1.83
100 film-coated tablets: V41.01 4  1: V1.64
100 film-coated tablets: V34.75 1  1: V0.34
10 film-coated tablets: V14.86 2  1: V2.97
30 film-coated tablets: V2673.87 1  1: V89.12
10 film-coated tablets: V70.39 1  1: V7.04
10 infusion bottles: V617.66 1 bottle: V61.77
100 tablets: V128.70 4  1: V5.14
100 tablets: V32.81 5  1: V1.64
30 capsules:V144.25 3  1: V14.42
50 capsules: V213.22 4  1: V17.05
Table 3 GKV-Medical and technical costs of different regimen for treating MDR-TB/XDR-TB (in V).
3.1: WHO standard (n Z 20)
Medication Costs/day Costs Costs 89 days Costs post-hospital
stay (- 89 days)
Amikacin 70.17 16842.24 6245.66 10596.58
Prothionamide 5.14 3088.80 458.18 2630.62
Moxifloxacin 7.04 4224.00 626.56 3597.44
Pyrazinamide 1.64 984.00 145.96 838.04
Terizidone 17.05 10234.80 1518.16 8716.64
35373.84 8994.52 26379.32
Injection via port 32.95 (2 injections Amikacin))  240 days
7908.00 2932.55 4975.45
Total 43281.84 11927.07 31354.77
3.2: Pyrazinamid replaced by ethambutol (n Z 4)
Medication Costs/day Costs Costs 89 days Costs post-hospital
stay (- 89 days)
Amikacin 70.17 16842.24 6245.66 10596.57
Prothionamide 5.14 3088.80 458.17 2630.62
Moxifloxacin 7.04 4224.00 626.56 3597.44
Ethambutol 1.640 984.24 145.99 838.24
Terizidone 17.05 10234.80 1518.16 8716.63
35374.08 8994.55 26379.53
Injection via port 32.95 (2 injections Amikacin)  240 days
7908.00 2932.55 4975.45
Total 43282.08 11927.10 31354.98
3.3: Ethambuto/Pyrazinamid replaced by Levofloxacin/Linezolid (n Z 15)
Medication Costs/day Costs Costs 89 days Costs post-hospital
stay (- 89 days)
Amikacin 70.17 16842.24 6245.66 10596.57
Prothionamide 5.14 3088.80 458.17 2630.62
Levofloxacin 2.97 1783.20 264.50 1518.69
Linezolid 44.56 26738.40 3966.19 22772.20
Terizidone 17.05 10234.80 1518.16 8716.63
58687.44 12452.70 46234.74
Injection via port 32.95 (2 injections Amikacin)  240 days
7908.00 2932.55 4975.45
Total 66595.44 15385.25 51210.19
3.4: Moxifloxacin/Levofloxacin replaced by ethambutol (n Z 4)
Medication Costs/day Costs Costs 89 days Costs post-hospital
stay (- 89 days)
Amikacin 70.17 16842.24 6245.66 10596.58
Ethambutol 1.64 984.24 145.99 838.25
Prothionamide 5.14 3088.80 458.17 2630.63
Pyrazinamide 1.64 984.00 145.96 838.04
Terizidone 17.05 10234.80 1518.16 8716.64
32134.08 8513.94 23620.14
Injection via port 32.95 (2 injections Amikacin)  240 days
7908.00 2932.55 4975.45
Total 40042.08 11446.49 28595.59
3.5: Ethambutol instead of Amikacin/Capreomycin (n Z 3)
Medication Costs/day Costs Costs 89 days Costs post-hospital
stay (- 89 days)
Ethambutol 1.64 984.24 145.99 838.24
Prothionamide 5.14 3088.80 458.17 2630.62
(continued on next page)
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Table 3 (continued )
3.5: Ethambutol instead of Amikacin/Capreomycin (n Z 3)
Medication Costs/day Costs Costs 89 days Costs post-hospital
stay (- 89 days)
Moxifloxacin 7.04 4224.00 626.56 3597.44
Pyrazinamide 1.64 984.00 145.96 838.04
Terizidone 17.05 10234.80 1518.16 8716.63
Total 19516.84 2894.85 16620.99
3.6: Capreomycin instead of amikacin (n Z 4)
Medication Costs/day Costs Costs 89 days Costs post-hospital
stay (- 89 days)
Capreomycin 149.35 35844.00 13292.15 22551.85
Prothionamide 5.14 3088.80 458.17 2630.62
Moxifloxacin 7.04 4224.00 626.56 3597.44
Pyrazinamide 1.64 984.00 145.96 838.04
Ethambutol 1.64 984.24 145.99 838.24
45125.04 14668.84 30456.20
Injection via port 18.30 (1 injection Capreomycin)  240 days
4392.00 1628.70 2763.30
49517.04 16297.54 33219.50
3.7: PAS, linezolid, clarithromycin, clofazimin (n Z 1)
Medication Costs/day Costs Cost 89 days Costs post-hospital
stay (- 89 days)
PAS 61.76 37059.60 5497.17 31562.42
Linezolid 44.56 26738.40 3966.19 22772.204
Terizidone 17.05 10234.80 1518.16 8716.63
Clarithromycin 1.93 1159.80 172.037 987.76
Clofazimin 1.83 1100.10 163.18 936.92
76292.70 11316.75 64975.95
Injection via port 18.30 (1 injection PAS)  600 days
10980.00 1628.70 9351.30
Total 87272.70 12945.45 74327.25
3.8: PAS, linezolid, isoniazid highly dosed, clofazimin (n Z 1)
Medication Costs/day Costs Cost 89 days Costs post-hospital
stay (- 89 days)
PAS 61.76 37059.60 5497.17 31562.42
Linezolid 44.56 26738.40 3966.19 22772.20
Terizidone 17.05 10234.80 1518.16 8716.63
Isoniazid highly dosed 1.47 883.92 131.11 752.80
Clofazimin 1.83 1100.10 163.18 936.92
76016.82 11275.83 64740.99
Injection via port 18.30 (1 injection PAS)  600 days
10980.00 1628.70 9351.30
Total 86996.82 12904.53 74092.29
3.9: PAS, Linezolid, rifabutin, clofazimin (n Z 1)
Medication Costs/day Costs Cost 89 days Costs post-hospital
stay (- 89days)
PAS 61.76 37059.60 5497.17 31562.43
Linezolid 44.56 26738.40 3966.19 22772.22
Rifabutin 14.42 8655.00 1283.82 7371.18
Terizidone 17.05 10234.80 1518.16 8716.64
Clofazimin 1.83 1100.10 163.18 936.92
83787.90 12428.54 71359.36
Injection via port 18.30 (1 injection PAS)  600 days
10980.00 1628.70 9351.30
Total 94767.90 14057.24 80710.66
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3.10: Linezolid, clofazimin, Amoxicillin/Clavulansa¨ure, clarithromycin (n Z 1)
Medication Costs/day Costs Cost 89 days Costs post-hospital
stay (- 89 days)
Linezolid 44.56 26738.40 3966.19 22772.21
Clofazimin 1.83 1100.10 163.18 936.92
Amoxicillin/Clav. 5.51 3306.48 490.46 2816.02
Terizidone 17.05 10234.80 1518.16 8716.64
Clarithromycin 1.93 1159.80 172.04 987.76
Total 42539.58 6310.04 36229.54
GKV Z Public Health Insurance in Germany (Gesetzliche Krankenversicherung).
Table 3 (continued)
Cost of multidrug resistance tuberculosis in Germanytreatment days as stated above) mean costs amounted to
V38,440.00.GKV costs of diagnosing and monitoring MDR-TB
As stated above, costs are charged to the GKV according to
the new Statutory Health Insurance Scheme 2013/2014,
multiplying the average number of points for all serviceFigure 1 Monte-Carlo simulation of the costs for medicatiotypes and providers as far as no fixed prices are given. The
GKV point value for Germany (“bundeseinheitlicher Ori-
entierungspunktwert”) in 2013 was V0.10. The calculation
tables show mean costs for diagnostics and monitoring,
separately for primary MDR-TB outpatients and MDR-TB
outpatients following primary hospitalization, with the
latter starting as outpatients after 89 days of inpatient
treatment from the 90th day of treatment (see Table 5).
Including linezolid or ethambutol results in additional costsn for different treatment options of primary outpatients.
Table 4 Weighted mean of drug costs.
Statistic Value
Mean V51,113.23
Standard deviation  V15,177.10
Minimum V19,516.84
Median V43,281.84
95% Confidence Interval V50,172.53 to V52,053.90
Maximum V94,767.90
Sum (n*Mean) V51,113,227.75
Size (n) 1000
Variance V230,344,234.06
Variance/Size V230,344.23
SQRT[Variance/Size] V479.94
SQRT Z square root.
1684 R. Diel et al.for ophthalmologic consultations. Performing again a Monte
Carlo-Simulation for monitoring costs according to the
weight of treatment options (figure not shown) the mean
result is V1,550.04 for monitoring initially hospitalized
patients (600 minus 89 days) with a range of V1,418.69 and
V1,602.64 and V2,192.13 for primary outpatients with a
range of V1957.01 and V2,263.82.
Purely outpatient costs
The costs for treating MDR-TB for primary outpatients have
to be calculated separately according to the therapeutic
regimen used and comprise the costs for diagnosing and
monitoring as well as the costs of medication: V2,192.13
plus V51,113.228 Z V53,305.358.
Inpatient costs
As far as inpatients are concerned, since 1 January 2004,
hospital costs are based on the uniform German DRG sys-
tem, which allocates each case to a diagnosis-related group
(see “Supplementary Material” section).
2 MDR-TB patients had to be assigned to the DRG cate-
gory E76C (V3,156.82 as “base rate”  0.964 as case
weight Z V6,086.34) and for 63 patients to be assigned to
E76A (89.06 days  V300.13 [18] as daily
reimbursement  63 patientsZ V1,683,963.40) resulting in
a weighted mean of ([V1,683,963.40 þ V6,086.34]: 65 pa-
tients) V26,000.76 per patient.
Total treatment costs
In 2012, of the 65 MDR-TB patients, 57 were hospitalized
(87.69%), so the weighted costs including the weighted drug
costs according to the least expensive treatment options
determined by the strain resistance patterns described
above are (V2,192.13 monitoring costs plus V51,113.23
drug for primary outpatients  [1-0.8769]) þ ([V38,440.01
drug costs for secondary outpatients following
hospitalization þ V1,550.04 remaining monitoring costsþ
V26,000.76 reimbursement for hospital
treatment]  0.8769) Z V6,561.89 þ V57,867.34 Z
V64,429.23.Calculation of loss of productivity due to TB
disease (indirect costs)
In accordance with the human capital approach, indirect
costs refer to the production loss for the national economy
caused by absence from the workplace due to sickness.
According to the Hanover Consensus [19] the productivity
losses should be evaluated without consideration of dif-
ferences in the branches, differences in age or sex, with
the average gross income for the period from non-self-
employed employment. Following the Scientific Institute
of the AOK, the biggest Public Health Insurance, the mean
sick leave period in 2012 due to TB is 29.12 days per case
[20]. If the employee pay per employee (2012: total
V37,126 [21] per day, i.e., divided by 365, is multiplied by
the 29 sick leave days, this results in an amount of V (2001:
V3,705.21) as average indirect costs per adult patient.
Multiplication by the gainfully employed rate for 2012
(72.6%) [22] then results in V2,150.37 (Table 6).
For MDR-TB patients the weighted productivity loss per
day (V101.715 x 0.726 Z V73.84) has to be multiplied by
the estimated number of days off work which clearly
exceed the mean sick leave duration per fully susceptible
TB case. Here, 2 options may be taken:
1) To restrict the sick leave duration to the intensive phase
of 240 days given that finally treatment success had been
achieved. In this case the indirect costs are: V17,721.60
(V73.84  240 days) for patients achieving treatment
success.
2) To suggest that productivity loss continue until the
entire treatment course of 20 months is fulfilled,
thereby gaining treatment success equivalent to full
capacity to work. This figure is most recently (in May
2014) promoted by the CDC, which estimate that the
indirect cost for those being treated between 20 and 26
months would amount to USD 126,000 [23]. Taking this
approach the indirect costs would amount to a total of
V44,304 (V73.84  600 days).
As information on the “real” sick leave duration is only
available for a small number of individual cases of the 65
MDR-TB/XDR-TB patients, the two figures should be used as
lower and upper limit.
Discussion
To date, published studies on the total treatment costs of
drug-resistant TB in Western Europe are sparse and often
incomplete: White et al. published a local UK survey
comprising 9 MDR-TB cases from 1996 to 1999 [24] treated in a
London hospital group in negative pressure rooms and calcu-
lated mean costs of £ 60,000 for “managing” a pulmonary
MDR-TB case. Blaas et al. [25] estimated the total inpatient
and outpatient drug costs for a single XDR-TB patient at
V176,000 in hisGermancase report.Diel et al.figured thecost
per MDR-TB patient in Germany but applied therapy only to
the WHO standard [11,26]. De Vries and Baltussen [27] per-
formed a very complex cost analysis of the 20MDR-TB patients
treated in the Netherlands in 2009 from a societal perspective
but no exact information was available on some cost drivers
Table 5 GKV costs of diagnosing MDR-TB and monitoring MDR-TB treatment (in V).
Medical services No. of
points
Individual
payment
(V)
Frequency Payment
(V)
Post-
hospital
First doctor’s visit (General practitioner)
Flat rate coverage (irrespective of number of visits by patients)
per quarter; 19e54 years of age (EBM 03000)a
122 12.20 11 (z11)b 134.20 134.20
Detailed conversation 90 9.00 9.00 9.00
Retainer fee (general practitioner), once per quarter (EBM 03040) 140 14.00 11 (z11) 154.00 154.00
Pneumological diagnostics (pulmonary TB)
Pneumological consultation; 6e59 years of age (EBM 13641) 202 20.46 7 (z6) 143.22 122.76
Pneumologist. bronchoscopy to avoid (EBM 13662) 988 100.08 1 (z0) 100.08 e
Pneumologist BAL (EBM 13663), additional fee on EBM 13662 242 24.51 1 (z0) 24.51 e
For amikacin or capreomycin treatment in MDReTB
Audiometry (EBM 09320), ENT code can also be applied 147 14.89 9 (z5) 134.01 74.45
Antibiotic drug serum levels (Amikacin etc.) EBM 32341 17.70 8 (z5) 141.60 88.50
Given ethambutol or linezolid treatment
Ophthalmologic consultation (EBM 06211)c 127 12.87 7 (z6) 90.09 76.68
Laboratory services
Intracutaneous test as per Mendel Mantoux (EBM 02200) e 0.91 1 (z0) 0.91 e
Tuberculin 2 TU RT 23 PPD (consultation requirement) e 9.15 1 (z0) 9.15 e
Transport fee per case (EBM 40100) per quarter e 2.60 6 (z5) 15.60 13,00
HBs-Ag (EBM 32781) e 5.50 1 (z0) 5.50 e
Microscopy test for mycobacteria (EBM 32176) e 5.20 23 (z18) 119.60 93.60
NAAT EBM 32825 e 61.40 1 (z0) 61.40 e
Culture test for mycobacteria (EBM 32747) per material e 34.90 22 (z18) 767.80 628.20
Differentiation of TB bacteria (EBM 32764) if positive e 28.40 1 (z0) 28.40 e
Resistance definition (EBM 32770) per mycobacteria type e 39.50e 1 (z0) 39.50 7.00
Magnesium (EBM 32248) e 1.40 8 (z5) 11.20 7.00
TSH (EBM 32101) e 3.00 4 (z3) 12.00 9.00
Chlorid (32084) e 0.25 8 (z5) 2.00 1.25
Natrium (EBM 32083) e 0.25 8 (z5) 2.00 1.25
Kalium (EBM 32081) e 0.25 8 (z5) 2.00 1.25
Calcium (EBM 32082) e 0.25 8 (z5) 2.00 1.25
Creatinine (Jaffe method) (EBM 32066) e 0.25 22 (z19) 5.50 4.75
Urea (EBM 32065) e 0.25 22 (z19) 5.50 4.75
Uric acid (EBM 32 064) e 0.25 20 (z19) 5.00 4.75
Blood count (EBM 32122) e 1.10 22 (z19) 5.50 4.75
Human Immunodeficiency Virus serology (EBM 32576) e 4.50 1 (z0) 4.50 e
Anti-HBc (EBM 32641) e 11.10 1 (z0) 11.10 e
Bilirubin total (EBM 32058) e 0.25 1 (z0) 0.25 e
Gamma-glutamyl transferase (EBM 32071) e 0.25 22 (z19) 5.50 4.75
Glutamate-oxaloacetate transaminase (EBM 32069) e 0.25 22 (z19) 5.50 4.75
Glutamate-pyruvate transaminase (EBM 32070) e 0.25 22 (z19) 5.50 4.75
X-ray (EBM 34241; a consultation cannot be charged)d 152 15.40 13 (z10) 200.20 154.00
Anti-HBcZ Hepatitis B core antibody; BALZ bronchoalveolar lavage; ENTZ Ear Nose Throat; HBs-AgZ surface antigen of the hepatitis
B virus; NAAT Z Nucleic Acid Amplification Test; TSH Z thyroid stimulating hormone.
z Following primary hospitalization.
a The ECG (EBM 03320) is included in the flat rate coverage and cannot be charged separately.
b Including 4 visits for referring to chest X-rays after the end of treatment.
c The sense of color test can only be charged as flat per quarter.
d Including 4 check-ups after the end of therapy.
e 7.9 x 5 different antibiotics tested. No reimbursement for additional testing of antibiotics.
Cost of multidrug resistance tuberculosis in Germanysuch as the cost differences between the treating hospitals
and on the frequency of expensive directly observed therapy
among the MDR-TB patients.
For the US, Rajbhandary et al. analyzed the inpatient
costs of 13 MDR-TB patients enrolled in a CDC study in
1995/1996 and estimated the remaining costs from asocietal perspective [28]. Marks et al. [29], in their
impressive population-based sample of 134 patients that
comprised 36% (130/364) of all MDR-TB and 56% (5/9) of
all XDR-TB cases reported in the United States during
2005e2007, calculated direct-plus-productivity-loss costs
of USD 260,000 per MDR-TB patients and USD 554,000 per
Table 6 Indirect costs per adult TB patient 2012.
Mean sick leave duration per TB case
(ICD 10: A15-A19) among of the AOK
29.12 days
Employee pay per employee
Total 2012 V37,126
Per day V101.72
Mean value 2012 (unweighted) V2,961.94
Gainfully employed rate 2012 72.6%
Mean value 2012 (weighted) V2,150.37
AOK Z Allgemeine Ortskrankenkasse; ICD Z International
Classification of Diseases; TB Z Tuberculosis.
1686 R. Diel et al.XDR-TB patient. The presentation of data for all patients
was limited, however, to the period of 1 year of
treatment.
In our present study we estimated the medical costs
based on the concrete resistance patterns of the strains of
all MDR-TB and XDR-TB patients as far those had been re-
ported in 2012. It is a limitation of the study that the
respective patients’ charts could not be analyzed on an in-
dividual basis, and possible extensions of therapy due to side
effects of the drugs and relapses during therapy could not be
taken into consideration. We further could not adjust the
costs to the mortality of 3.1% of MDR-TB patients in 2012 [4]
as the date of death during treatment was unknown, the
latter possibly resulting in a slight overestimation of the
suggested costs for 20 months of treatment. However, these
costs could dramatically rise in the future if the small pro-
portion of 7.2% of XDR-TB cases among the total of MDR-TB
cases (4/55) increases, resulting e as shown above e in a
more complex and consequently more costly combination of
the few remaining susceptible drugs.
In our bundle of therapeutic options of known XDR-TB
strains, drug costs may increase up to about V95,000. So
far, that figure has little impact on the current mean es-
timate because its fraction is still comparatively low.
Nevertheless, and irrespective of the strains’ resistance
patterns, productivity loss due to the long duration of
treatment (as a rule, 20 months) plays a significantly
higher role than in fully susceptible TB, in which absen-
teeism from work is on average limited to 29 days (see
Table 6). Adding mean-weighted treatment costs of
V64,429.229 to the possible range of indirect costs be-
tween V17,721 and V44,304 results in total cost from a
societal perspective of between V82,150 and V108,733
per MDR-TB/XDR-TB case.
In conclusion, our cost analysis based on strain resis-
tance patterns allows correction of the previously under-
estimated costs for MDR-/XDR-TB in Germany. Further
evaluation within the framework of a nationwide survey is
needed to assess the real contribution of productivity loss
to the total costs for MDR-TB/XDR-TB.Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.rmed.2014.09.021.References
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